Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
The cellular mechanism underlying the CGS mediated
2025-03-03

The cellular mechanism underlying the CGS12066-mediated inhibition of glutamate release from hippocampal nerve terminals through presynaptic 5-HT1B receptors remains to be elucidated. 5-HT1B receptors are coupled to PTX-sensitive G proteins (Gi or Go) that have been shown to inhibit AC activity as w
-
Having taken a step back from affinity to gain
2025-03-03

Having taken a step back from affinity to gain better exposure and solubility, we started work to replace the unstable oxazolinone, and address the selectivity over the hERG channel. Keeping in mind the binding mode of the series from crystal structures, triazole was identified as another mildly aci
-
Pyrimidine is the important pharmacology core in
2025-03-03

Pyrimidine is the important pharmacology core in many Aurora inhibitors, such as VX-680, ENMD-2076, CYC-116 and ENMD-2076 [12]. To identify additional effective Aurora inhibitors, we designed a series of 2,4-diaminopyrimidine compounds, our modeling studies suggested that the influence of size on Ca
-
br Results and discussion br Conclusion In summary a series
2025-03-03

Results and discussion Conclusion In summary, a series of indazole-based derivatives were synthesized and SAR studies conducted, with view to the development of a novel Aurora kinases inhibitor. The carboxylic loxo 101 group extending from the C-3 position of the aniline and substituted group
-
In the case of DIA CN the docking results do
2025-03-01

In the case of DIA-4CN the docking results do not show any interaction between the iron atom and the inhibitor, presumably due to the reduced ability to form a complex involving the -CONN- moiety versus the bidentate -CONHNH- central group of HYD-4Me. This results in a considerable gap between the i
-
br Material and methods br Results br Discussion
2025-03-01

Material and methods Results Discussion T2D is a substantial threat to global human health [31]. Obesity-associated chronic low-grade inflammation promotes insulin resistance and T2D [32]. In obese individuals, the production of numerous inflammatory molecules including IL-6 and TNF-a is up
-
In conclusion there are only a few experimental
2025-03-01

In conclusion, there are only a few experimental reports evaluating the influence of kn 47 on allergy. With the exception of studies using macrolides, most point to their harmful effect on the severity of this disease. Future studies will be crucial to define the impact of antibiotic use on allergy
-
While high fat diet models of insulin resistance are accepta
2025-03-01

While high-fat diet models of insulin resistance are acceptable approaches for the study of pre-diabetes in humans, they are not suitable for modeling progression towards established type2 diabetes. The pattern of activation of the lipoxygenase pathway in pre-clinical models of type2 diabetes has no
-
br Development of lorlatinib from crizotinib to a
2025-03-01

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
br Conflict of interest statement br Introduction Currently
2025-03-01

Conflict of interest statement Introduction Currently, adenocarcinoma is the most common histological subtype of lung cancer. Activating mutations and translocations with a potential for targeted therapy are reported predominantly in non-smokers. ALK rearrangement is found in less than 5% of u
-
It is well known that TCDD is the most potent
2025-03-01

It is well-known that TCDD is the most potent ligand of AhR and it regulates gene expression, such as CYP1A1, via activation of AhR (Mimura and Fujii-Kuriyama, 2003). Besides Tomblin et al. (2016) have recently shown that TCDD via AhR regulated L-type amino kanamycin sulfate transporter 1 expressio
-
The excellent potencies selectivities and improved
2025-03-01

The excellent potencies, selectivities and improved PK associated with the piperazine class triggered more extensive off-target screenings of the highlighted compounds. A screen of more than 100 enzymes, receptors, and ion channels resulted in activity at the norepinephrine transporter (NET). This m
-
In the past years the
2025-03-01

In the past 10 years, the role of the CD73-adenosinergic pathway in suppression of anti-tumor immunity has increasingly been recognized [13], [14]. In this review, we discuss the latest findings dealing with the regulation of anti-tumor immunity by CD73 and adenosine. We also discuss ongoing clinica
-
br Roles for GMF in Endocytic
2025-03-01

Roles for GMF in Endocytic Traffic In addition to its roles in cell migration, GMF regulates actin-dependent endocytosis in yeast and mammals 13, 14, 50, and promotes the turnover of focal adhesions in immune PSB11 hydrochloride 42, 51. Vinculin, a central component of focal adhesions that ancho
-
br Mechanisms of specific immunotherapy Several mechanisms m
2025-03-01

Mechanisms of specific immunotherapy Several mechanisms may be involved in specific immunotherapy of EAMG by active immunization with the therapeutic vaccine in IFA. During the therapy, the therapeutic benefits result from diversion of autoantibody specificities away from pathogenic extracellular
13605 records 31/907 page Previous Next First page 上5页 3132333435 下5页 Last page